



# The power of automation: Transition from manual to automated chemotherapy compounding: main issues to consider

María-José Tamés

Assistant Director

Pharmacy Department

Onkologikoa Foundation

San Sebastian (Spain)



Conflict of interest: Nothing to disclose



# The power of automation

## Transition from manual to automated

### chemotherapy compounding: main issues to consider

María-José Tamés

Assistant Director

Pharmacy Department

Onkologikoa Foundation


San Sebastian (Spain)




# Onkologikoa Foundation

- **Cancer center**
- **Non profit private hospital owned by a foundation**
- **Agreement with Basque health service**
- **Building equipped with state of the art technology**
- **Technological development top priority**
- **Electronic patient records (paperless hospital) 2008**







Manual → Semi-automated → Automated

# Manual → Semi- Automated preparation

- 2009: Starting point for semi-automation
- Aim:
  - **Patient safety**
  - **Efficiency** (productivity)
  - **Standardization** (quality)
  - **Clinical traceability** (information for outcomes)
- Product identification
- Gravimetry

# Product identification based on location management




SAFE linking between 2 bar codes:

- Bar code of the NC on the package
- Bar code of a location



# Gravimetric method flow



# Traceability

Tratamientos de Quimioterapia 2

Administración

Información de tratamientos a

Trazabilidad del proceso

10152176

Nº prescripción: 1234875 | Nº TTO: 1206920

Medicamento	Dosis Nominal	Dosis Gravimétrica	%	B/M
DOXORRUBICINA 50 mg vial	71.00	70.26 mg	-1.05	Balanza

Proceso	Fecha	Hora	Usuario
PRESCRIPCIÓN	17/03/2011	10:22:13	ARRATE PLAZAOLA ALCIBAR
VALIDACIÓN	17/03/2011	10:24:45	MARIA JOSE TAMES ALONSO
GENERACIÓN ETIQUETAS	17/03/2011	10:30:55	MARÍA JOSÉ ARGANDOÑA ESNAL
BANDEJAS	17/03/2011	10:33:33	MARÍA JOSÉ ARGANDOÑA ESNAL
PREPARACIÓN	17/03/2011	10:43:42	BEGOÑA GARCÍA MACHÍN
DISPENSACIÓN	17/03/2011	10:50:35	MARÍA JOSÉ ARGANDOÑA ESNAL
ADMINISTRACIÓN	17/03/2011	11:16:28	KONTXI AGIRRE SARASUA

Medicamento	Medicamento
10152175 FISIOLÓGICO bolsa 100 ml - ONDANSETRON - FORTECORTIN	10152176 FISIOLÓGICO bolsa 50 ml - DOXORRUBICINA
10152177 FISIOLÓGICO bolsa 50 ml - CICLOFOSFAMIDA	10152178 FISIOLÓGICO bolsa 250 ml - DOCETAXEL

Historia

Fecha	Esquema
28/04/2011	TAC
07/04/2011	TAC
17/03/2011	TAC
24/02/2011	TAC
03/02/2011	TAC

En la lista: 32

Velocidad

Estado	Modo
En la lista de Administración	B
En la lista de Administración	B
En la lista de Administración	B
En la lista de Administración	B



Tratamientos de Quimioterapia 2

Archivo Tratamientos Agendas Resultados Mantenimiento Utilidades Editar Ayuda

Hoja de trabajo

GERARDO CAJARAVILLE ORDOÑANA  
(Puestos: 3\*/CBxTeclado)

0000130033

Viales	Porciones	Medicamento	Vol TOTAL/UNITARIO	AHORRO
1	<input type="checkbox"/>	FISIOLOGICO bolsa 1000 ml /14CI7105, 09/09/2011		0
3	<input checked="" type="checkbox"/>	- PACLITAXEL vial 30 mg /09F03KG, 30/06/2011		0
2	<input type="checkbox"/>	- PACLITAXEL vial 100 mg /09G21PB, 30/07/2011	47.50	0

BADEJAS

CB 10112807  
8400101128078

CONFIRMAR 8400101128078 Cancelar 8400101128078

PACK de códigos de barras.

CB asociados	
1	10112807


Usar	Id	Medicamento	Lote	Caducidad	Queda..
<input checked="" type="checkbox"/>	2728	PACLITAXEL vial 30 mg	09F03KG	04/03/2010	<input type="checkbox"/>
<input type="checkbox"/>	2740	PACLITAXEL vial 30 mg	09F03KG	05/03/2010	<input type="checkbox"/>

NUM


Semi - Automated



Automated



# Automated compounding added-value



# Productivity

- Relative term
- Open-minded approach
- Look at productivity considering other issues



# Compounding time of a Technician ??

Variable. Depends on several factors:

- Training and individual capability of each technician
- Work organisation
- Semi-automated systems (identification/gravimetry)
- Close systems usage
- GMPs application level
- Preparation complexity (reconstitution, large volumes, large vials number)




# Compounding time of a Robot ??

Variable. Depends on several factors:

- System configuration: different options
- Preparation complexity
  - Reconstitution
  - Volume
  - Number of different drugs/cycle
  - Number of vials
  - Final product (syringe, bag, elastomeric pump, etc.)

# Organisation of the preparation cycles preparations selection

Increase final products/minimize robot tasks



- Increase capacity of vials-carousel
  - Multi-dose vials
  - Preparation by drug
- Reuse syringe for same drug
- Final product conditions
  - If possible don't remove volume

- Productivity: Mean **preparations/ hour = 9** (for cycles  $\geq 6$  prep)

# Robots are not appropriate to meet demand at peak times. Production has a constant rhythm


- Robotic compounding requires a rethinking of compounding workflow
- Preparation “in advance” (before administration)
  - “Prescriptions for the following day”
  - Preparation by batches (Dose banding )
  - Anticipated reconstitution
  - Anticipated preparation (before prescription)




### Conventional flow



### Anticipated dose preparation flow



### Modified Conventional flow




**We only discard 3,2% of anticipated preparations**

# What is the impact in human resources??

## Comparison with manual production

- Case by case analysis: variable efficiency, human redundancy (safety)

# Compounding cycle times



■ Steps depending on the user  
■ **Autonomous step**

**One hour of robot provides 33 free min. to the user  
more than 3.5 hours /day**

# Additional considerations include

- Range of final containers offered: syringes, bags, elastomeric pumps, cassettes...
- Flexibility on disposable brands, preparation types and configuration options
- Simultaneous automatic compounding and material management tasks (waste disposal, partially used vials...) to increase productivity
- Technical support from the provider company
- Ease of integration into the cleanroom
- Connectivity with hospital systems (interfacing)
- Cleaning & decontamination procedures: feasibility of implementation

# Conclusions

- Chemotherapy robotic compounding is a novel technology that is here to stay and is evolving continuously.
- It offers clear advantages to manual and semi-automated compounding
- Robotic productivity definitely improves if we optimize the circuit and readapt our workflow processes.
- The selection of a specific robot requires a thorough analysis
- A cost minimization analysis alone, might not be a fair and proper approach in its implementation




Thanks for your  
attention

[mjtames@onkologikoa.org](mailto:mjtames@onkologikoa.org)




## Automated Chemotherapy compounding:

- A. Provides added value just related to patient safety
- B. Provides to preparations the same accuracy than a well-trained technician
- C. Obtains higher productivity than a manual procedure
- D. Can handle 100% of the production of the unit
- ✓ E. None correct




# Automated Chemotherapy compounding:




## Productivity of a robot for chemotherapy compounding:

- A. Is always a fixed parameter for each robot brand
- B. Is the main issue to consider when buying a chemotherapy compounding robot
- C. Relies only in the capacity for vials in the port-carousel (parking lot) of the robot.
- D. Relies on the expertise of the operator
- ✓ E. None correct




## Productivity of a robot for chemotherapy compounding:



# Implementation of a robot in the chemotherapy compounding process:

- A. Will help to deal with high demand in the outpatient clinic at peak times
- ✓ B. Might require rethink or redesign the existing compounding workflow of the unit
- C. Is not adequate for preparation by batches (dose banding)
- D. Will save at least 1 technician position
- E. None correct



## Implementation of a robot in the chemotherapy compounding process:

